17 May 2022 - Recent studies have examined strategic behaviours in the pharmaceutical industry that extend patent and regulatory protection, known alternatively as “lifecycle management” or “evergreening.”
This literature highlights the extent to which the patent system is increasingly focused on granting new protections for minor modifications of existing innovations.